Revvity signs for space at Bruntwood SciTech’s Alderley Park
With sites in Oxford and Cambridge already operational, the life sciences and diagnostics firm has opted to open a 6,000 sq ft lab at the Cheshire campus.
Revvity, which is embarking on a research collaboration with Genomics England and NHS England on the Generation Study – a programme aiming to sequence the genomes of 100,000 newborns to improve early diagnosis of rare genetic conditions – has signed a multi-year lease.
Chris Hughes, managing director for North Europe at Revvity, said: “As our work with Genomics England enters an exciting new chapter, so do we. Our UK expansion is about more than simply establishing a presence, it’s about unlocking new opportunities for collaboration and innovation.”
It is expected that Revvity will partner with various health tech firms already based at Bruntwood SciTech’s Alderley Park, including Medicines Discovery Catapult, CellCentric, Globachem Discovery, global software developers SAP.
Hughes added: “With access to world-class lab infrastructure and unrivalled connectivity to the NHS collaborators and industry peers, our new Alderley Park base will be central to supporting the delivery of the Generation Study as one of the study’s extraction and sequencing collaborators.
“The Generation Study will help enable earlier diagnoses and better outcomes for newborns, while supporting our broader mission to push the boundaries of what’s possible in healthcare.”
Mark Julian, associate commercial director, Bruntwood SciTech, said: “Supporting the growth of pioneering innovation businesses is central to our mission at Alderley Park.
“By delivering state-of-the-art workspace, tailored to specialist needs of companies like Revvity – alongside access to investment, skilled talent and potential collaborators – we can help these market-leading innovators grow and thrive, creating jobs and economic value across Cheshire and Greater Manchester.”
He described Revvity’s decision to come to Alderley Park as a “clear endorsement” of the campus.
“By joining a thriving community of over 250 science, technology and innovation-led businesses, Revvity is perfectly placed to collaborate and make meaningful scientific advances.
“We’re thrilled to support not only Revvity’s UK growth, but also its collaboration with Genomics England. Their presence will strengthen our network of health innovators and make real world impactful changes to science, with benefits that will be felt far beyond Alderley Park.”
